-
Russia, North Korea connect road bridge ahead of summer opening
-
'Strangled': Pakistan faces economic imperative in Iran war peace push
-
Michael Jackson fans pack Hollywood for biopic premiere
-
Turkey arrests 110 coal miners on hunger strike
-
Associated British Foods to spin off Primark clothes brand
-
Pope visits Eq. Guinea on last stop of Africa tour
-
Hello Kitty's parent company to make own video games
-
Di Matteo says 'vital' for faltering Chelsea to add experience
-
Ex-Spurs star Davids condemns 'lack of quality, lack of management'
-
Turkmenistan, the gas giant increasingly dependent on China
-
Romanian AI music sensation Lolita sparks racism debate
-
Timberwolves battle back to stun Nuggets in NBA playoffs
-
Eta appointment 'no surprise' for Union Berlin's ascendant women
-
Democrats eye Virginia gains in war with Trump over US voting map
-
Tourists trickle back to Kashmir, one year after deadly attack
-
Inside the world of ultra-luxury wedding cakes
-
Chinese AI circuit board maker soars on Hong Kong debut
-
Oil prices dip, most stocks rise on lingering Iran peace hopes
-
Tim Cook's time as Apple chief marked by profit absent awe
-
Mitchell, Harden shine as Cavs down Raptors for 2-0 series lead
-
El Salvador's missing thousands buried by official indifference
-
Trump's Fed chair pick to face lawmakers at key confirmation hearing
-
PGA Tour to scrap Hawaii opening events from 2027
-
Amazon invests another $5 bn in Anthropic
-
Israel PM vows 'harsh action' against soldier vandalising Jesus statue in Lebanon
-
Wembanyama wins NBA defensive player of the year
-
'The Devil Wears Prada 2' stars reunite for glamorous premiere
-
El Salvador holds mass trial of nearly 500 alleged gang members
-
Apple's Tim Cook to step down as CEO in September
-
West Ham's draw at Palace relegates Wolves, piles pressure on Spurs
-
Canadian tourist killed in Mexico archaeological site shooting
-
Wolves relegated from Premier League
-
Oil jumps on Hormuz tensions, stocks mostly retreat
-
Colombian environmental activist honored amid threats and exile
-
Gun battle traps more than 200 tourists at Rio viewpoint
-
Alcaraz may skip French Open rather than rush injury comeback
-
Top US court to hear case of Catholic schools excluded from state funding
-
Trump Fed chair pick to vow interest rate independence at key hearing
-
EU to host Taliban officials for talks on deporting Afghans
-
Blue Origin probing rocket's failure to deliver satellite
-
Wembanyama 'changing the game as we speak', says Nowitzki
-
Swiss football club turn down Kanye West concert approach
-
Leicester fairytale turns sour as relegation to third tier looms
-
Pope Leo blasts 'exploitation' as he wrap up tour of resource-rich Angola
-
Varma ton revives Mumbai's IPL hopes with win over Gujarat
-
Formula One makes rule changes after drivers' criticism
-
Singer D4vd charged with murder over teen's body found in Tesla
-
UK PM denies misleading MPs, says officials hid Mandelson info
-
Tit-for-tat blockades once again cripple traffic in Hormuz
-
Cafu says 2026 World Cup is perfect time for Brazil to win again
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
K.Hofmann--VB